COSCIENS Biopharma Says 'Although Further Analysis of the Study Results Is Required, Initial Review of the Results Indicates That the Comparator Tests May Have Led to a High False Positive Rate Which Impacted Macimorelin's Ability to Reach the Primary...

Benzinga · Aug 27 19:33

COSCIENS Biopharma Says 'Although Further Analysis of the Study Results Is Required, Initial Review of the Results Indicates That the Comparator Tests May Have Led to a High False Positive Rate Which Impacted Macimorelin's Ability to Reach the Primary Efficacy Endpoint.'

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

COSCIENS Biopharma Says 'Although Further Analysis of the Study Results Is Required, Initial Review of the Results Indicates That the Comparator Tests May Have Led to a High False Positive Rate Which Impacted Macimorelin's Ability to Reach the Primary...

COSCIENS Biopharma Says 'Although Further Analysis of the Study Results Is Required, Initial Review of the Results Indicates That the Comparator Tests May Have Led to a High False Positive Rate Which Impacted Macimorelin's Ability to Reach the Primary Efficacy Endpoint.'

Risk Disclaimer